Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q3 2023 · 10-Q
Revenue—
Net Income-$45.85M-$45.85MN/M vs Q3 2022 EPS Diluted-$0.26-$0.26N/M vs Q3 2022 Operating Income-$42,905,000N/M Operating Cash Flowderived-$40,188,000—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Free Cash Flowderived-$41,686,000— ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end